Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nanobiotix S.A. ADR
(NQ:
NBTX
)
4.050
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nanobiotix S.A. ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why Is Clearfield (CLFD) Stock Down 28% Today?
May 05, 2023
Clearfield (CLFD) stock is falling on Friday after the company released its earnings report for the fiscal second quarter of 2023.
Via
InvestorPlace
Why is Trupanion (TRUP) Stock Down 32% Today?
May 05, 2023
Trupanion (TRUP) stock is taking a beating on Friday after the pet medical insurance company released its earnings report for Q1 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 05, 2023
Via
Benzinga
Why Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?
May 05, 2023
Galmed Pharmaceuticals (GLMD) stock is gaining on Friday after the company announced an investment agreement with OnKai.
Via
InvestorPlace
Why is Nanobiotix (NBTX) Stock Up 107% Today?
May 05, 2023
Nanobiotix (NBTX) stock is taking off on Friday after the company revealed details about ongoing contract negotiations for NBTXR3.
Via
InvestorPlace
Why Carvana Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
May 05, 2023
Gainers
Via
Benzinga
Why Are Nanobiotix Shares Plummeting Today?
April 25, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 05, 2023
Good morning! We're diving into the biggest pre-market stock movers traders will want to keep an eye on for Friday morning!
Via
InvestorPlace
NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company
May 05, 2023
Company agreed to term sheet as of May 3, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
April 27, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 27, 2023
Via
Benzinga
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 25, 2023
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 25, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 25, 2023
Via
Benzinga
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results
April 24, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
April 17, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
April 11, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Earnings Scheduled For April 24, 2023
April 24, 2023
Companies Reporting Before The Bell • Dynex Cap (NYSE:DX) is estimated to report quarterly earnings at $0.17 per share on revenue of $6.99 million.
Via
Benzinga
Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
March 27, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
March 14, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
February 14, 2023
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
January 11, 2023
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
December 27, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
December 21, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
December 08, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 15, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
November 14, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Posts Updated Data For Radiotherapy-Activated Cancer Therapy In Head & Neck Cancer Patients
November 10, 2022
Via
Benzinga
NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer
November 10, 2022
Data to be discussed during Nanobiotix Q3 Earnings Call at 8:00AM EST
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
November 09, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.